Game,
As I have posted previously, IMO Cardiogenics would be wise to help their share price by announcing that patients have begun to be enrolled in the Beta Site Head-to-Head study. If they issue this PR I would encourage them not to identify the number of patients enrolled to date, if enrollment rate is in line with their projected rates they could make a simple statement confirming this fact.
Ante